Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety
Phase 4
132
about 5.7 years
12–17
1 site in OH
What this study is about
Researchers are testing whether a personalized approach to escitalopram dosing improves anxiety treatment in children. Participants will be randomly assigned to either standard or pharmacogenetically-guided escitalopram, based on their genetic makeup. The trial will last 2094 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Escitalopram
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
escitalopram (SSRI; increases serotonin availability)
oral (Oral Tablet)
Secondary: Tolerability-Activation
Psychiatry / Mental Health